CXCL10/IP-10/CRG-2 Antibody (33008R) [Unconjugated]

Recombinant Human CXCL10/IP‑10/CRG‑2 protein was serially diluted 2-fold and captured by Mouse Anti-Human CXCL10/IP‑10/CRG‑2 Monoclonal Antibody (Catalog # MAB2661) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL10/IP‑10/CRG‑2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-266-NA) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).

• Reactivity: Hu
• Applications: ELISA
• Clone: 33008R
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL10/IP-10/CRG-2 Antibody (33008R) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL10/IP-10/CRG-2
  Val22-Pro98
  Accession # P02778.2
• Specificity: Detects human CXCL10/IP-10/CRG-2 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody (33008R) [Unconjugated]

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta , TNF-alpha , IL-12, and viruses. Additional cell types that have been shown to express CXCL10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, CRG-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T-lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent antitumor effect. A chemokine receptor specific for CXCL10 and Mig has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

1. Loetscher, M. et al. (1996) J. Exp. Med. 184:963.
2. Wang, X. et al. (1996) J. Biol. Chem. 271:24286.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P02778.2()